Its symptoms include superficial peeling of small areas of the skin that involve the dorsal and palmar surfaces of the hands and feet, superficial scaling of forearms and legs, and acanthosis. Peeling skin syndrome 6
Peeling skin syndrome 6 is caused by a genetic defect in the filaggrin (filaggrin family member 2) gene. The function for this gene is vital for normal cellular-cell adhesion within the cornified cell layers. It is also critical for the integrity and mechanical strength of the stratum corneum of the epidermis. Its symptom include dryness of the skin, peeling of the skin. erythema at lesion sites, bullae, and hyper-pigmentation. Symptoms and signs
Abnormal blistering of the skin
Abnormality of hair texture
Dry skin
Aminoaciduria
Hyperhidrosis
Ichthyosis

Treatment
There is no remedy for peeling skin syndrome. Treatment focuses on avoiding skin damage and treating symptoms as they occur. Ointments are also used to minimize skin peeling and when the blister grows, sterile needles may be activated. The condition can be exacerbated by hot temperatures, humidity, and friction. Individuals should be informed to avoid exacerbating triggers such as trauma, humidity, heat, perspiration, and water. Frequency
Only several dozen cases have been reported in the literature, making it rare, but because its symptoms are mild and similar to other disorders it could very well be under-diagnosed. See also
Idiopathic calcified nodules of the scrotum
Keratolysis exfoliativa
List of cutaneous conditions
Corneodesmosin
TGM5
Carbohydrate sulfotransferase
Cystatin A
Serpin
Filaggrin

References


== External links ==
Treatment-resistant depression
The combination medicine dextromethorphan/bupropion is approved for treatment-resistant major depressive disorder due to its action on the NMDA receptor. Available forms
Dextromethorphan is available alone in the form of cough syrup and pills as well as in combination with other agents. As a pharmaceutical drug, it is available as dextromethorphan/quinidine (Nuedexta) for the treatment of pseudobulbar affect and as dextromethorphan/bupropion (Auvelity) for treatment-resistant major depressive disorder. Contraindications
Because dextromethorphan can trigger a histamine release (allergic reaction), atopic children, who are especially susceptible to allergic reactions, should be administered dextromethorphan only if absolutely necessary, and only under the strict supervision of a healthcare professional. Adverse effects
Side effects of dextromethorphan at normal therapeutic doses can include:

A rare side effect is respiratory depression. Neurotoxicity
Dextromethorphan was once thought to cause Olneys lesions when administered intravenously; however, this was later proven inconclusive, due to lack of research on humans. Tests were performed on rats, giving them 50 mg or more every day for as long as a month. Neurotoxic changes, including vacuolation, have been observed in posterior cingulate and retrosplenial cortices of rats administered other NMDA receptor antagonists such as PCP, but not with dextromethorphan. Dependence and withdrawal
In many documented cases, dextromethorphan has produced psychological dependence in people who used it recreationally. It is considered less addictive than other common cough suppressants, such as the weak opiate codeine. Since dextromethorphan also acts as a serotonin reuptake inhibitor, users report that regular recreational use over a long period of time can cause withdrawal symptoms similar to those of antidepressant discontinuation syndrome.